Doctor's DEA License Yanked After Missing Hearing Deadline
Published Date: 3/20/2025
Notice
Summary
Dr. Margaret Sprague from California lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to defend herself, so the DEA officially revoked her certificate. This means she can’t prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked, Cannot Prescribe
The DEA revoked Margaret Sprague, M.D.'s Certificate of Registration No. FS8371267, effective April 21, 2025. Because her California medical license was revoked on or about November 30, 2023, she is not allowed to prescribe, dispense, or otherwise handle controlled substances, which directly affects her medical practice and patients.
Pending Renewal and New Registrations Denied
The DEA denied any pending applications of Margaret Sprague, M.D., to renew or modify Certificate No. FS8371267 and denied any other pending application for additional registration in California, effective April 21, 2025. This prevents her from regaining or expanding DEA authority to handle controlled substances in California while the order stands.
Default for Not Requesting Hearing Allows Final Order
The Order notes that when a registrant served with an Order to Show Cause fails to file a written request for a hearing, they are deemed to have waived the hearing right and to be in default. In such a default, DEA may file for final agency action and the Administrator may enter a default final order under 21 CFR 1316.67.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Previous / Next Documents
Previous: 2025-04753, William Needham, N.P.; Decision and Order
William Needham, a nurse practitioner from Mississippi, lost his DEA registration because he no longer has the state authority to handle controlled substances. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately, with no money penalties mentioned.
Next: 2025-04755, National Institute of Dental & Craniofacial Research; Notice of Closed Meeting
The National Institute of Dental & Craniofacial Research is holding a closed virtual meeting on April 22, 2025, to review special grant applications about Organs-on-a-Chip technology for dental research. This meeting affects researchers applying for funding and keeps sensitive info private. No money changes are announced, but the grant review could impact future research funding decisions.